Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Serina Therapeutics announced the completion of enrollment and dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial for SER-252, an investigational therapy for advanced Parkinson’s disease, ahead of the third quarter 2026 timeline. The independent Safety Monitoring Committee will review safety and tolerability data next to deter…